New variants of SARS-CoV-2, vaccine immune response and the Brazilian reality

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a highly pathogenic β-coronavirus, is the etiologic agent of coronavirus disease 2019 (COVID-19), which gave rise to a difficult to control pandemic, especially in Brazil. Approximately 4,000 mutations have been identified in SARS-CoV-2, with the majority being redundant without having any biological effect on the virus. The aim of the present study was to objectively understand how new SARS-CoV-2 variants can affect vaccine response, in addition to highlighting the current situation in Brazil in the face of the pandemic and considering epidemiological and immunological aspects of COVID-19. The main protective correlate investigated in most vaccines is the neutralizing antibody titer induced by immunizing agents, observed in the pre-clinical phase in animals, whose action is to block the binding of the spike protein to the angiotensin-converting enzyme 2 (ACE2) receptor, preventing infection. Up to the second half of 2021, the variants that are of greatest concern worldwide and require molecular surveillance are Alpha variant (or B.1.1.7 lineage), Beta (or B.1.351 lineage), Gamma (or P1 lineage) and Delta (or B.1.617.2 lineage). Brazil finds itself in a highly unfavorable scenario, with the circulation of variants of concern, mainly Gamma and Delta, with high fatality rates for COVID-19 and low vaccination rate. Given the still latent situation of the COVID-19 pandemic in Brazil, the lack of global planning for action strategies for non-pharmacological prevention measures, there is an imminent risk of the emergence of new variants due to the finding of susceptible hosts and the high proliferative rate of SARS-CoV-2. It is urgent to increase the genotyping of positive samples isolated from infected individuals, the speed of vaccination of the entire population and the unification of non-pharmacological preventive measures throughout the country.

Keywords

Severe acute respiratory syndrome coronavirus 2 / coronavirus disease 2019 / variants / vaccine / Brazil

References

[1] Candido DS, Claro IM, de Jesus JG, Souza WM, Moreira FRR, Dellicour S, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science. 2020; 369: 1255-60.

[2] Fernandes LAC, da Silva CAF, Dameda C, de Bicalho PPG. Covid-19 and the Brazilian reality: the role of favelas in combating the pandemic. Front Sociol. 2020; 5: 611990.

[3] Brasil tem quase 30% da população-alvo vacinada com primeira dose contra Covid-19 [Internet]. Brazil: Ministry of Health of Brazil. c2021 [cited 2021 Aug 23]. Available from: https://www.gov.br/saude/pt-br/assuntos/noticias/brasil-tem-quase-30-da-populacao-alvo-vacinada-com-primeira-dose-contra-covid-19

[4] Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020; 180: 1081-9.

[5] Janik E, Niemcewicz M, Podogrocki M, Majsterek I, Bijak M. The emerging concern and interest SARS-CoV-2 variants. Pathogens. 2021; 10: 633.

[6] Erol A. Are the emerging SARS-COV-2 mutations friend or foe? Immunol Lett. 2021; 230: 63-4.

[7] Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020; 1: 100040.

[8] de Almeida JO, de Oliveira VRT, Avelar JLD, Moita BS, Lima LM. COVID-19: physiopathology and targets for therapeutic intervention. Rev Virtual Quim. 2020; 12: 1464-97. Portuguese.

[9] Meckiff BJ, Ramírez-Suástegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4⁺ T cells in COVID-19 . Cell. 2020; 183: 1340-53.e16.

[10] Jin P, Li J, Pan H, Wu Y, Zhu F. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther. 2021; 6: 48.

[11] Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020; 586: 583-8. Erratum in: Nature. 2021;590:E25.

[12] Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020; 53: 724-32.e7.

[13] Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021; 10: 100208.

[14] da Fonseca Lima EJ, Almeida AM, de Ávila Kfouri R. Vacinas para COVID-19 - o estado da arte. Rev Bras Saude Mater Infant. 2021; 21 Suppl 13- 9. Portuguese.

[15] Palacios R, Batista AP, Albuquerque CSN, Patiño EG, Santos J do P, Tilli Reis Pessoa Conde M, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. SSRN 3822780 [Preprint]. 2021 [cited 2021 Aug 23]. Available from: https://papers.ssrn.com/abstract=3822780

[16] Sauré D, O’Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis. 2021;S1473-3099: 00479-5.

[17] Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L, et al. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021; 27: 1109-17.

[18] Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far? Viruses. 2021; 13: 1192.

[19] Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021; 372: eabg3055.

[20] Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021; 593: 142-6.

[21] Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med. 2021; 384: 1468-70.

[22] Imai M, Halfmann PJ, Yamayoshi S, Iwatsuki-Horimoto K, Chiba S, Watanabe T, et al. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proc Natl Acad Sci U S A. 2021; 118: e2106535118.

[23] Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021; 596: 276-80.

[24] COVID-19 Delta variant detected in 98 countries, continues to evolve and mutate, warns WHO [Internet]. United Unions: UN News. c2021 [cited 2021 Aug 23]. Available from: https://news.un.org/en/story/2021/07/1095252

[25] Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021; 595: 17-8.

[26] Callaway E. Fast-spreading COVID variant can elude immune responses. Nature. 2021; 589: 500-1.

[27] Variante delta pode levar a aumento de casos de Covid-19 no Brasil [Internet]. Brazil: Ministry of Health of Brazil. c2021 Abril Mídia S A. Todos os direitos reservados [cited 2021 Aug 23]. Available from: https://saude.abril.com.br/medicina/variante-delta-pode-levar-a-aumento-de-casos-de-covid-19-no-brasil/

[28] Castro MC, Kim S, Barberia L, Ribeiro AF, Gurzenda S, Ribeiro KB, et al. Spatiotemporal pattern of COVID-19 spread in Brazil. Science. 2021; 372: 821-6.

[29] Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021; 29: 747-51.e4.

[30] Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021; 184: 2939-54.e9.

[31] De Souza WM, Amorim MR, Sesti-Costa R, Coimbra LD, Toledo-Teixeira DA, Parise PL, et al. Levels of SARS-CoV-2 lineage P.1 neutralization by antibodies elicited after natural infection and vaccination. SSRN 3793486 [Preprint]. 2021 [cited 2021 Mar 1]. Available from: http://dx.doi.org/10.2139/ssrn.3793486

[32] Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern. BioRxiv 457229 [Preprint]. 2021 [cited 2021 Aug 23]. Available from: https://www.biorxiv.org/content/10.1101/2021.08.23.457229v1